Renalytix PLC
LSE:RENX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Renalytix PLC
Cash from Investing Activities
Renalytix PLC
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Renalytix PLC
LSE:RENX
|
Cash from Investing Activities
-$122k
|
CAGR 3-Years
-3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Craneware PLC
LSE:CRW
|
Cash from Investing Activities
-$15.3m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-23%
|
|
|
Cambridge Cognition Holdings PLC
LSE:COG
|
Cash from Investing Activities
-£26k
|
CAGR 3-Years
48%
|
CAGR 5-Years
7%
|
CAGR 10-Years
15%
|
|
|
Feedback PLC
LSE:FDBK
|
Cash from Investing Activities
-£582k
|
CAGR 3-Years
20%
|
CAGR 5-Years
14%
|
CAGR 10-Years
-21%
|
|
|
Doctor Care Anywhere Group PLC
ASX:DOC
|
Cash from Investing Activities
-£2.8m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
P
|
Physitrack PLC
STO:PTRK
|
Cash from Investing Activities
-€3.1m
|
CAGR 3-Years
40%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
Renalytix PLC
Glance View
Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.
See Also
What is Renalytix PLC's Cash from Investing Activities?
Cash from Investing Activities
-122k
USD
Based on the financial report for Dec 31, 2025, Renalytix PLC's Cash from Investing Activities amounts to -122k USD.
What is Renalytix PLC's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 3Y
-3%
The average annual Cash from Investing Activities growth rates for Renalytix PLC have been -3% over the past three years .
